Results 111 to 120 of about 36,254 (205)

Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 9, Page 1219-1233, November 2026.
Summary of a multicentre TriNetX study evaluating outcomes after percutaneous coronary intervention (PCI) in patients with cirrhosis. Cirrhosis was associated with higher 1‐year gastrointestinal bleeding and mortality, especially with decompensated disease.
Dhir Gala, Sameer Rao, Manas Gunani, Kajol Shah, Anand V. Kulkarni, Karn Wijarnpreecha, Daniel Q. Huang, Pojsakorn Danpanichkul, Ahmed Al‐Khazraji, Kaveh Hajifathalian, Vivek Lingiah, Paul Gaglio, Nikki Duong, Christine Gerula   +13 more
wiley   +1 more source

Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban

, 2014
Treatment with the new oral anticoagulant rivaroxaban can be associated with severe liver injury.; We report 2 patients with predominantly hepatocellular liver injury that had onset during treatment with rivaroxaban.
Heim, Markus, Terracciano, Luigi, Rätz Bravo, Alexandra E., Krähenbühl, Stephan, Liakoni, Evangelia, Rätz Bravo, Alexandra E, Krähenbühl S, Heim M, Terracciano L, Liakoni E, Rätz Bravo AE   +10 more
core   +1 more source

Natural History and Factors Influencing 90‐Day Clinical Outcomes and 1‐Year Recurrence of Thalamic Stroke

Brain and Behavior, Volume 16, Issue 10, October 2026.
ABSTRACT Objective To investigate the natural course of cerebral small vessel disease (CSVD) manifested as pure thalamic infarction (PTI) and identify predictors of 90‐day clinical prognosis and 1‐year recurrent major adverse cardiovascular/cerebrovascular events (MACE).
Huang Qiang, Cui Ying, Zhang Yongbo
wiley   +1 more source

A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk

Frontiers in Cardiovascular Medicine
ObjectiveRivaroxaban and dabigatran are approved to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF). However, the clinical benefits of rivaroxaban and dabigatran in people with high bleeding risk are unclear.MethodsA ...
Penghui Liu
doaj   +1 more source

Rivaroxaban HPLC-MS/MS method comparison.

, 2017
Rivaroxaban HPLC-MS/MS method comparison.
Claudio Ernesto Albers Mendes (3723241), Carlos Eduardo dos Santos Ferreira (3344150), Priscilla Bento Matos Derogis (3723232), Marcelo Katz (695963), Livia Rentas Sanches (3723250), Carolina Nunes França (386340), Valdir Fernandes de Aranda (3723244), Marjorie Paris Colombini (3723238), João Carlos de Campos Guerra (3723235), Cristóvão Luis Pitangueira Mangueira (3723253), Adriana Caschera Leme Faulhaber (3723247)   +10 more
core   +1 more source

Next‐Generation Sequencing‐Based Molecular Profiling and Management of Advanced Solid Tumors: A Real‐World Experience in a Community‐Based Academic Cancer Center

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Advances in molecular and cell biology have led to a paradigm shift in cancer management. We implemented next‐generation sequencing (NGS) at our community‐based academic cancer center over a decade ago. We sought to optimize the use of genomics and understand its impact in identifying actionable genomic alterations to determine ...
Gayathri Moorthy, Annette Sereika, Karen Kaul, Megan Parilla, Mir B. Alikhan, Michael Bouma, Dyson Wake, Peter J. Hulick, Henry M. Dunnenberger, Linda M. Sabatini, Mathew Yang, Kathy A. Mangold, Erin Proctor, Nicholas Evans, Nicholas Miller, Donald L. Helseth Jr, Darryck Maurer, Justin Brueck, Janardan Khandekar, Bruce Brockstein   +19 more
wiley   +1 more source

In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments

Frontiers in Pharmacology
BackgroundApixaban (API) and rivaroxaban (RIVA) are orally available inhibitors of coagulation factor Xa and are commonly used to treat cancer-related venous thrombosis.
Zihan Liu, Zihan Liu, Wenyu Du, Wenyu Du, Qimin Wang, Zhi Wang, Jing An, Yinling Ma, Zhanjun Dong, Ying Li   +9 more
doaj   +1 more source

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US

, 2016
Jeffrey D Miller,1 Xin Ye,2 Gregory M Lenhart,1 Amanda M Farr,1 Oth V Tran,1 W Jackie Kwong,2 Elizabeth A Magnuson,3 William S Weintraub41Truven Health Analytics Inc, Cambridge, MA, 2Daiichi Sankyo Inc, Parsippany, NJ, 3St Luke Mid-America Heart ...
Miller JD, Tran OV, Kwong WJ, Farr AM, Magnuson EA, Weintraub WS, Ye X, Lenhart GM   +7 more
core  

Treatment of Deep Vein Thrombosis in Congenital Factor VII Deficiency: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Managing thrombosis in patients with bleeding disorders requires careful assessment of thromboembolic and bleeding risks, tailoring antithrombotic treatment in terms of type, dose, and duration, and considering the need for replacement therapy based on individual factor levels and bleeding history.
Synnøve Gjelsten Mortensen, Lars Erik Laugsand, Martin Syvertsen Mykland, Erik Magnus Berntsen, Tobias S. Slørdahl   +4 more
wiley   +1 more source

Rivaroxaban alleviates hepatic sinusoidal obstruction syndrome in mice by modulating the gut microbiota and inhibiting the PI3K/Akt signaling pathway

Frontiers in Microbiology
IntroductionHepatic sinusoidal obstruction syndrome (HSOS) is a vascular liver disease with a high mortality rate, and treatment methods are limited. Rivaroxaban is an oral anticoagulant.
Wencheng Liu, Yanbin Cheng, Xue Han, Junlin Xia, Qingyu Wei, Bing Chang, Quansheng Li   +6 more
doaj   +1 more source